CA2328348A1 — 2-methylpropionic acid derivatives and medicinal compositions containing the same
Assigned to Kissei Pharmaceutical Co Ltd · Expires 1999-10-21 · 27y expired
What this patent protects
The present invention provides novel 2-methylpropionic acid derivatives represented by the general formula: (see formula I) (wherein R1 represents a hydrogen atom, a lower alkyl group or an aralkyl group; R2 represents a hydrogen atom, a lower alkyl group or a halogen atom; A r…
USPTO Abstract
The present invention provides novel 2-methylpropionic acid derivatives represented by the general formula: (see formula I) (wherein R1 represents a hydrogen atom, a lower alkyl group or an aralkyl group; R2 represents a hydrogen atom, a lower alkyl group or a halogen atom; A represents an oxygen atom or an imino group; the carbon atom marked with (R) represents a carbon atom in R configuration; and the carbon atom marked with (S) represents a carbon atom in S configuration) and pharmaceutically acceptable salts thereof, which have excellent .beta.3-adrenoceptor stimulating effects and are useful as agents for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of biliary tract.
Drugs covered by this patent
- Myrbetriq (MIRABEGRON) · Apgdi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.